MarketCapExport financials
Atara Biotherapeutics (ATRA)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Atara Biotherapeutics ATRA
$ 8.27
1.1%
Facebook
X
Telegram
Atara Biotherapeutics Financial Ratios 2025-2011 | ATRA
Brief overview of Atara Biotherapeutics's market valuation
Current figures are compared with the company's own five-year history for 2018–2022.
Key multiples at the end of the period are P/S 0.61x (median 0.5x), P/B 4.1x (median 4.1x). Ratios sit near their own comparison base, with an average deviation of +10.7% from five-year medians.
Capital efficiency is characterized by ROE -84.9%, ROA 161.5%, ROCE -93.1%. The business is not generating positive returns on invested resources. Valuation should be read cautiously until earnings recover.
The cash cycle accelerated by 114.2 days to 4.1 days. Less capital is tied up in operations.
Valuation takeaway
Atara Biotherapeutics's profile looks neutral, with price and fundamental efficiency broadly aligned.
Annual Financial Ratios Atara Biotherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.3 | -0.6 | -0.0 | -2.3 | -4.3 | -4.7 | -2.4 | -6.9 | -10.1 | -4.6 | -8.1 | -4.3 | - | - | - | |
P/S |
0.6 | 0.4 | 0.3 | 8.2 | - | - | - | - | - | - | - | - | - | - | - |
EPS |
2.6 | -11.4 | -65.2 | -2.2 | -3.6 | -4.2 | -5.7 | -5.3 | -4 | -2.8 | - | - | - | - | - |
EV (Enterprise Value) |
124 M | 232 M | 242 M | 676 M | 1.56 B | 1.38 B | 676 M | 1.58 B | 1.16 B | 326 M | 449 M | 102 M | 11.2 M | 3.81 M | - |
EBITDA per Share |
3.03 | -10.5 | -64 | -2.69 | -3.53 | -4.07 | -5.63 | -5.33 | -4.04 | -2.81 | -2.28 | -5.65 | - | - | - |
EV/EBITDA |
3.3 | -3.0 | -0.9 | -2.5 | -4.7 | -4.6 | -2.2 | -6.5 | -9.3 | -3.9 | -7.5 | -3.5 | - | - | - |
PEG |
0.01 | -0.0 | -0.0 | 0.42 | -0.54 | -0.31 | 0.32 | 0.22 | 0.22 | 0.2 | -0.13 | 0.01 | - | - | - |
P/B |
-1.9 | -0.5 | -0.0 | 4.1 | 5.3 | 3.1 | 2.4 | 4.7 | 6.8 | 1.4 | 1.5 | 1.2 | - | - | - |
P/CF |
-1.4 | -0.7 | -0.0 | -1.9 | -6.7 | -8.0 | -2.9 | -7.3 | -11.2 | -5.8 | -12.4 | -7.3 | - | - | - |
ROE % |
-84.90 | 87.79 | -278.27 | -180.28 | -121.65 | -66.32 | -100.07 | -68.08 | -67.18 | -31.15 | -18.16 | -27.14 | - | - | - |
ROA % |
161.54 | -78.28 | -166.84 | -60.65 | -72.66 | -52.14 | -84.85 | -58.88 | -54.87 | -29.95 | -17.61 | -26.39 | - | - | - |
ROCE % |
674.99 | 327.52 | -124.47 | -94.29 | -93.96 | -61.17 | -96.56 | -67.39 | -63.92 | -31.95 | -18.54 | -27.23 | - | - | - |
Current Ratio |
0.3 | 0.5 | 0.6 | 1.5 | 2.5 | 4.7 | 7.4 | 8.0 | 6.2 | 26.9 | 33.4 | 38.9 | - | - | - |
DSO |
4.1 | 50.4 | 1582.3 | 118.3 | - | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Atara Biotherapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.15 | -0.32 | -0.29 | -0.3500000000000001 | -0.32 | 0.2 | 3.53 | -0.07000000000000028 | -2.93 | -3.1 | -5.65 | -13.919999999999995 | -16.4 | -16.91 | -0.72 | -0.7300000000000002 | -0.82 | 0.18 | -0.87 | -0.96 | -0.9 | -0.91 | -0.86 | -0.9400000000000004 | -0.92 | -1.14 | -1.2 | -1.3499999999999996 | -1.31 | -1.6 | -1.44 | - | -1.29 | -1.15 | -1.05 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.19 | -0.31 | -0.24 | -6.86 | -0.26 | 0.26 | 3.63 | -10.9 | -2.83 | -2.85 | -5.4 | -2.04 | -16.1 | -16.8 | -0.71 | -187 | -0.82 | -0.3 | -0.86 | -72.2 | -0.88 | -0.89 | -0.83 | -20.9 | -0.89 | -1.12 | -1.19 | -36.5 | -1.29 | -1.59 | -1.44 | - | -1.3 | -1.17 | -1.06 | - | -1.03 | -0.95 | -0.89 | - | -0.9 | -0.68 | -0.6 | - | -0.44 | -0.62 | -0.42 | 0.01 | - | -3.39 | -5.6 | - | -2.61 | - | - | -5.58 | - | - | - | - | - | - | - |
ROE % |
38.90 | 44.77 | 24.89 | -55.24 | -51.04 | -38.58 | -14.59 | 86.73 | 12.76 | 125.85 | -845.28 | -992.69 | -990.65 | -1172.89 | -211.76 | -135.93 | -110.43 | -92.79 | -125.23 | -105.59 | -89.79 | -83.50 | -78.55 | -87.99 | -97.40 | -98.97 | -110.65 | -104.91 | -95.13 | -87.57 | -67.80 | -44.47 | -61.95 | -60.15 | -59.56 | -47.33 | -57.33 | -47.28 | -38.39 | -23.97 | -27.73 | -22.48 | -17.94 | -11.42 | -21.62 | 7.85 | 8.22 | 4.30 | 37.52 | 122.09 | -6.83 | - | 23.02 | - | - | 110.28 | - | - | - | - | - | - | - |
ROA % |
-72.53 | -74.82 | -45.36 | 36.64 | 41.84 | 40.75 | 18.04 | -62.44 | -87.33 | -108.95 | -121.56 | -127.10 | -110.39 | -96.25 | -63.16 | -60.58 | -60.72 | -56.70 | -79.28 | -71.89 | -65.78 | -65.29 | -65.04 | -74.79 | -83.86 | -85.23 | -94.25 | -90.11 | -82.12 | -75.40 | -58.86 | -38.46 | -52.74 | -50.44 | -49.23 | -38.65 | -48.27 | -41.14 | -34.82 | -23.04 | -26.70 | -21.68 | -17.34 | -11.07 | -20.99 | -28.27 | -27.93 | -31.75 | -26.72 | -4.25 | -6.64 | - | -4.89 | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-129.68 | -134.52 | -86.92 | 210.85 | 307.00 | 500.43 | 544.96 | 473.33 | 398.39 | 171.01 | 70.62 | -164.08 | -162.43 | -127.55 | -94.68 | -92.48 | -92.87 | -87.60 | -101.75 | -89.49 | -79.88 | -76.78 | -73.62 | -83.92 | -93.78 | -95.28 | -106.03 | -100.83 | -91.92 | -85.16 | -66.81 | -44.15 | -60.80 | -58.36 | -57.16 | -45.09 | -55.29 | -46.31 | -38.34 | -24.58 | -28.47 | -23.06 | -18.34 | -11.63 | -21.88 | 8.03 | 8.42 | 4.52 | 37.93 | 121.73 | -6.86 | - | 23.16 | - | - | 109.82 | - | - | - | - | - | - | - |
Current Ratio |
0.3 | 0.4 | 0.3 | 0.3 | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | 0.5 | 0.6 | 0.6 | 0.8 | 1.0 | 1.3 | 1.5 | 2.0 | 2.4 | 2.3 | 2.5 | 3.2 | 3.6 | 4.1 | 4.7 | 7.9 | 9.1 | 6.4 | 6.6 | 7.9 | 6.5 | 8.0 | 7.4 | 7.4 | 7.4 | 7.4 | 5.5 | 5.5 | 5.5 | 5.5 | 25.9 | 25.9 | 25.9 | 25.9 | 32.9 | 32.9 | 32.9 | 32.9 | 36.1 | 21.0 | 36.1 | 36.1 | 29.6 | 29.6 | - | - | - | - | - | - | - | - | - | - |
DSO |
37.6 | 23.0 | 110.8 | 90.6 | 25.3 | 23.0 | 4.8 | 2.2 | 0.2 | 0.5 | 0.8 | 7.5 | 17.1 | 52.4 | 55.8 | 330.3 | 17.4 | 1.3 | 8.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
273.1 | - | - | - | 825.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | 2.2 | 0.2 | 0.5 | 0.8 | 7.5 | 17.1 | 52.4 | 55.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | 2.2 | 0.2 | 0.5 | 0.8 | 7.5 | 17.1 | 52.4 | 55.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Atara Biotherapeutics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Longeveron
LGVN
|
$ 3.27 | 15.14 % | $ 57.5 B |  USA |
 |
Grifols, S.A.
GRFS
|
$ 8.85 | 1.03 % | $ 6.02 B |  Spain |
 |
Incyte Corporation
INCY
|
$ 122.28 | 1.65 % | $ 23.9 B | USA |
 |
AC Immune SA
ACIU
|
$ 2.26 | -1.53 % | $ 228 M |  Schweiz |
 |
Aldeyra Therapeutics
ALDX
|
$ 0.65 | 2.67 % | $ 39 M | USA |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M |  Canada |
 |
Precision BioSciences
DTIL
|
$ 9.12 | -4.0 % | $ 117 M | USA |
 |
AIM ImmunoTech
AIM
|
$ 0.15 | 6.3 % | $ 243 K | USA |
 |
MediWound Ltd.
MDWD
|
$ 13.81 | -2.13 % | $ 376 M |  Israel |
 |
Ascendis Pharma A/S
ASND
|
$ 258.99 | 0.94 % | $ 15.7 B |  Danmark |
 |
ANI Pharmaceuticals
ANIP
|
$ 71.09 | -0.22 % | $ 1.43 B | USA |
 |
Actinium Pharmaceuticals
ATNM
|
$ 1.59 | 1.27 % | $ 49.6 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.24 | -6.06 % | $ 330 M |  Britain |
 |
BridgeBio Pharma
BBIO
|
$ 79.53 | 1.09 % | $ 15.2 B | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
$ 7.66 | 1.73 % | $ 1.61 B | USA |
 |
Bicycle Therapeutics plc
BCYC
|
$ 3.69 | -0.14 % | $ 256 M | Britain |
 |
Coherus BioSciences
CHRS
|
$ 0.58 | -8.97 % | $ 67.9 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
$ 28.37 | 3.6 % | $ 3.61 B | USA |
 |
Cellectis S.A.
CLLS
|
$ 1.35 | 21.62 % | $ 135 M |  France |
 |
BeyondSpring
BYSI
|
$ 0.64 | 10.75 % | $ 26.3 M | USA |
 |
Alkermes plc
ALKS
|
$ 47.94 | 3.16 % | $ 7.9 B |  Irlanda |
 |
Altimmune
ALT
|
$ 1.94 | -0.21 % | $ 171 M | USA |
 |
Cardiff Oncology
CRDF
|
$ 0.76 | -4.57 % | $ 50.8 M | USA |
 |
Novartis AG
NVS
|
$ 160.35 | -1.79 % | $ 311 B | Schweiz |
 |
Citius Pharmaceuticals
CTXR
|
$ 0.49 | -1.36 % | $ 5.42 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
$ 9.32 | -0.75 % | $ 255 M | Israel |
 |
Arrowhead Pharmaceuticals
ARWR
|
$ 49.35 | 0.71 % | $ 6.6 B | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
$ 16.22 | -0.49 % | $ 2.18 B | Canada |
 |
Cullinan Management
CGEM
|
$ 11.33 | 0.89 % | $ 683 M | USA |
 |
BioNTech SE
BNTX
|
$ 87.68 | 0.54 % | $ 21.2 B |  Germany |
 |
Collegium Pharmaceutical
COLL
|
$ 24.8 | 1.35 % | $ 785 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
$ 3.99 | 1.53 % | $ 53.1 M | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
$ 1.24 | 3.33 % | $ 56.7 M | Israel |
 |
AnaptysBio
ANAB
|
$ 48.73 | 0.72 % | $ 1.41 B | USA |
 |
Assembly Biosciences
ASMB
|
$ 22.36 | 4.73 % | $ 251 M | USA |
 |
Adagene
ADAG
|
$ 2.14 | 4.39 % | $ 126 M |  China |
 |
Benitec Biopharma
BNTC
|
$ 9.47 | 2.05 % | $ 441 M | USA |
 |
Denali Therapeutics
DNLI
|
$ 19.74 | -0.55 % | $ 3.41 B | USA |
 |
Amarin Corporation plc
AMRN
|
$ 11.68 | -0.64 % | $ 4.85 B | Irlanda |
 |
ImmuCell Corporation
ICCC
|
$ 10.19 | -0.7 % | $ 92 M | USA |
 |
Editas Medicine
EDIT
|
$ 2.38 | -4.99 % | $ 211 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
$ 32.84 | 3.38 % | $ 1.9 B | USA |
 |
Cue Biopharma
CUE
|
$ 19.08 | 1.71 % | $ 1.81 B | USA |
 |
Equillium
EQ
|
$ 1.41 | -3.09 % | $ 80.8 M | USA |
 |
Black Diamond Therapeutics
BDTX
|
$ 1.61 | 0.63 % | $ 91.6 M | USA |
 |
Abeona Therapeutics
ABEO
|
$ 2.35 | -4.28 % | $ 124 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
$ 18.38 | 0.55 % | $ 3.09 B | USA |
 |
PainReform Ltd.
PRFX
|
$ 0.74 | -6.69 % | $ 480 K | Israel |
 |
Atossa Therapeutics
ATOS
|
$ 2.04 | -4.67 % | $ 17.6 M | USA |